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In Response:
We thank Dr. Detterbeck for
his interest and thoughtful comments
about our systematic review. We agree
with him that measuring fluorodeoxy-
glucose (FDG) uptake by using the stan-
dardized uptake value (SUV) is subject
to many different sources of impreci-
sion, as described in our discussion and
further delineated in his letter.
Several working groups have re-
cently developed guidelines for FDG
positron emission tomography (PET)
acquisition to help direct the research
community.1,2 These guidelines suggest
that the resolution of PET scanners
should be no less than half the tumor
size diameter. These same guidelines
suggest using a 12-mm region of interest
centered around the most intense FDG
uptake defined as “peak” SUV. Thus,
SUV measurements for tumors smaller
than 2.5 cm in size may yield important
clinical information.
We agree with Dr. Detterbeck that
tumor size is a potentially important
confounding variable, because it is
clearly associated with both the “expo-
sure” (FDG uptake) and, arguably, with
the outcome (survival). Accordingly,
multivariable analysis is both necessary
and sufficient to adjust for the confound-
ing influence of tumor size.3
Two studies in our systematic re-
view found that SUV was a significant
predictor of survival after adjusting for
tumor size.4,5 In addition, we recently
completed a study of prognosis in 75
patients with clinical stage Ia non-small
cell lung cancer (NSCLC) and found
that SUV was a significant predictor of
survival both before and after adjust-
ment for tumor size (hazard ratio: 1.21,
95% confidence interval 1.01–1.45 per 1
unit increment in SUVmax). There was a
significant interaction between SUVmax
and tumor size, such that the magnitude of
the association between FDG uptake and
survival was even stronger for patients
with tumors larger than 18 mm (mean
tumor diameter in our study).6 Of note,
only three of the nine studies in our review
provided data on tumor size for patients
with stage I NSCLC; in these studies, the
mean diameters were 14, 24, and 31 mm,
respectively.4,7,8 We did not examine the
effect of histology or attenuation charac-
teristics because this information was not
provided in the primary studies.
We continue to believe, along
with others in the field, that a large,
prospective, multicenter trial using stan-
dardized protocols is necessary to fully
examine the potential use of PET FDG
uptake as a biomarker for prognosis in
NSCLC. We hope that our review stim-
ulates additional interest in performing
such a study.
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